Previous 10 | Next 10 |
AIMIA'S LARGEST SHAREHOLDER REMINDS FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD PRIOR TO PROXY VOTING DEADLINE Canada NewsWire In order to be counted at the annual meeting of shareholders, proxies must be received by 10:30 a.m. (Eastern Daylight Time) on April 14, 2023 ...
OCALA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseas...
2023-04-03 11:24:04 ET AIM ImmunoTech Inc. (AIM) Q4 2022 Earnings Conference Call April 03, 2023, 08:30 AM ET Company Participants Thomas Equels - CEO Chris McAleer - Ph.D. Scientific Officer Conference Call Participants Jason McCarthy - Maxim Ed Woo ...
2023-04-03 06:37:57 ET AIM ImmunoTech press release ( NYSE: AIM ): FY GAAP EPS of -$0.40. Revenue of $0.14M (flat Y/Y). For further details see: AIM ImmunoTech GAAP EPS of -$0.40, revenue of $0.14M
– Company continues to execute across development pipeline of high-value indications with 12 active clinical programs – Well-positioned to achieve multiple near-term, value-driving milestones – Company to host inaugural conference call and webcast today at 8...
2023-03-30 17:35:02 ET AIM , ELBM , VERB For Seeking Alpha's full earnings season calendar, click here . For further details see: Notable earnings after Friday's close
OCALA, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseas...
OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral disea...
OCALA, Fla., March 16, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral disea...
AIMIA REPORTS FOURTH QUARTER 2022 RESULTS Canada NewsWire (All figures in Canadian dollars unless otherwise noted) TORONTO , March 16, 2023 /CNW/ - Aimia Inc. (TSX: AIM) reported its financial results for the three months and twelve months ended De...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...